Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)

Veronica Dioverti; Zeinab El Boghdadly; Zainab Shahid; Alpana Waghmare; Maheen Z. Abidi; Steven Pergam; Michael Boeckh; Sanjeet Dadwal; Mini Kamboj; Susan Seo; Roy F. Chemaly; Genovefa A. Papanicolaou

doi:10.1016/j.jtct.2022.09.002

Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)

Veronica Dioverti, Zeinab El Boghdadly, Zainab Shahid, Alpana Waghmare, Maheen Z. Abidi, Steven Pergam, Michael Boeckh, Sanjeet Dadwal, Mini Kamboj, Susan Seo, Roy F. Chemaly, Genovefa A. Papanicolaou

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) and is an update of pervious publication. Since our original publication in 2020, the NIH and IDSA have published extensive guidelines for management of COVID-19 which are readily accessible ( NIH Guidelines, IDSA Guidelines ). This update focuses primarily on issues pertaining specifically to HCT/cellular therapy recipients. Information provided in this manuscript may change as new information becomes available.

Original language	English (US)
Pages (from-to)	810-821
Number of pages	12
Journal	Transplantation and Cellular Therapy
Volume	28
Issue number	12
DOIs	https://doi.org/10.1016/j.jtct.2022.09.002
State	Published - Dec 2022

Keywords

Cellular therapy
COVID-19
Hematopoietic cell transplantation
SARS-CoV-2

ASJC Scopus subject areas

Immunology and Allergy
Molecular Medicine
Hematology
Cell Biology
Transplantation

Access to Document

10.1016/j.jtct.2022.09.002

Cite this

Dioverti, V., Boghdadly, Z. E., Shahid, Z., Waghmare, A., Abidi, M. Z., Pergam, S., Boeckh, M., Dadwal, S., Kamboj, M., Seo, S., Chemaly, R. F., & Papanicolaou, G. A. (2022). Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022). Transplantation and Cellular Therapy, 28(12), 810-821. https://doi.org/10.1016/j.jtct.2022.09.002

Dioverti, V, Boghdadly, ZE, Shahid, Z, Waghmare, A, Abidi, MZ, Pergam, S, Boeckh, M, Dadwal, S, Kamboj, M, Seo, S, Chemaly, RF & Papanicolaou, GA 2022, 'Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)', Transplantation and Cellular Therapy, vol. 28, no. 12, pp. 810-821. https://doi.org/10.1016/j.jtct.2022.09.002

@article{49fa9cdcddd94dedbc74dcd47b89ab7e,

title = "Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)",

abstract = "This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) and is an update of pervious publication. Since our original publication in 2020, the NIH and IDSA have published extensive guidelines for management of COVID-19 which are readily accessible ( NIH Guidelines, IDSA Guidelines ). This update focuses primarily on issues pertaining specifically to HCT/cellular therapy recipients. Information provided in this manuscript may change as new information becomes available.",

keywords = "Cellular therapy, COVID-19, Hematopoietic cell transplantation, SARS-CoV-2",

author = "Veronica Dioverti and Boghdadly, {Zeinab El} and Zainab Shahid and Alpana Waghmare and Abidi, {Maheen Z.} and Steven Pergam and Michael Boeckh and Sanjeet Dadwal and Mini Kamboj and Susan Seo and Chemaly, {Roy F.} and Papanicolaou, {Genovefa A.}",

note = "Publisher Copyright: {\textcopyright} 2022 The American Society for Transplantation and Cellular Therapy",

year = "2022",

month = dec,

doi = "10.1016/j.jtct.2022.09.002",

language = "English (US)",

volume = "28",

pages = "810--821",

journal = "Transplantation and Cellular Therapy",

issn = "2666-6367",

publisher = "Elsevier BV",

number = "12",

}

TY - JOUR

T1 - Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)

AU - Dioverti, Veronica

AU - Boghdadly, Zeinab El

AU - Shahid, Zainab

AU - Waghmare, Alpana

AU - Abidi, Maheen Z.

AU - Pergam, Steven

AU - Boeckh, Michael

AU - Dadwal, Sanjeet

AU - Kamboj, Mini

AU - Seo, Susan

AU - Chemaly, Roy F.

AU - Papanicolaou, Genovefa A.

PY - 2022/12

Y1 - 2022/12

N2 - This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) and is an update of pervious publication. Since our original publication in 2020, the NIH and IDSA have published extensive guidelines for management of COVID-19 which are readily accessible ( NIH Guidelines, IDSA Guidelines ). This update focuses primarily on issues pertaining specifically to HCT/cellular therapy recipients. Information provided in this manuscript may change as new information becomes available.

AB - This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) and is an update of pervious publication. Since our original publication in 2020, the NIH and IDSA have published extensive guidelines for management of COVID-19 which are readily accessible ( NIH Guidelines, IDSA Guidelines ). This update focuses primarily on issues pertaining specifically to HCT/cellular therapy recipients. Information provided in this manuscript may change as new information becomes available.

KW - Cellular therapy

KW - COVID-19

KW - Hematopoietic cell transplantation

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85140787630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140787630&partnerID=8YFLogxK

U2 - 10.1016/j.jtct.2022.09.002

DO - 10.1016/j.jtct.2022.09.002

M3 - Article

C2 - 36103987

AN - SCOPUS:85140787630

SN - 2666-6367

VL - 28

SP - 810

EP - 821

JO - Transplantation and Cellular Therapy

JF - Transplantation and Cellular Therapy

IS - 12

ER -

Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this